BR0312621A - Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap) - Google Patents
Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap)Info
- Publication number
- BR0312621A BR0312621A BR0312621-8A BR0312621A BR0312621A BR 0312621 A BR0312621 A BR 0312621A BR 0312621 A BR0312621 A BR 0312621A BR 0312621 A BR0312621 A BR 0312621A
- Authority
- BR
- Brazil
- Prior art keywords
- vpac2
- peptides
- agonists
- pacap
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
"AGONISTAS DE RECEPTOR (VPAC2) DE PEPTìDEO DE ATIVAçãO DE PITUITáRIA ADENILATO CICLASE (PACAP)". A presente invenção refere-se a novos peptídeos que funcionam in vivo como agonistas do receptor VPAC2. Estes polipeptídeos de secretagogo de insulina são mostrados reduzirem a glicose sang³ínea in vivo mais do que os controles do desafio de glicose. Os polipeptídeos desta invenção são também estáveis em formulação e possuem meia-vida longa. Os peptídeos da presente invenção fornecem uma terapia nova para pacientes com secreção de insulina endógena diminuída, em particular diabéticos do tipo 2. Em particular, a invenção é um polipeptídeo selecionado de um grupo específico de polipeptídeos relacionados com VPAC2, ou equivalentes funcionais destes. A invenção é também direcionada a um método de tratar uma doença metabólica em um mamífero compreendendo administrar uma quantidade terapeuticamente eficaz dos peptídeos de secretagogo de insulina ao referido mamífero. São também descritos os métodos de preparar os peptídeos, tanto recombinantes e sintéticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39573802P | 2002-07-12 | 2002-07-12 | |
PCT/US2003/021761 WO2004006839A2 (en) | 2002-07-12 | 2003-07-11 | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312621A true BR0312621A (pt) | 2005-12-06 |
Family
ID=30115918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312621-8A BR0312621A (pt) | 2002-07-12 | 2003-07-11 | Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap) |
Country Status (20)
Country | Link |
---|---|
US (2) | US7378494B2 (pt) |
EP (1) | EP1578358A2 (pt) |
JP (1) | JP2006506969A (pt) |
CN (1) | CN101405298A (pt) |
AR (1) | AR040548A1 (pt) |
AU (1) | AU2003267990A1 (pt) |
BR (1) | BR0312621A (pt) |
CA (1) | CA2491279A1 (pt) |
DO (1) | DOP2003000669A (pt) |
GT (1) | GT200300142A (pt) |
HN (1) | HN2003000217A (pt) |
IL (1) | IL165499A (pt) |
MX (1) | MXPA04012305A (pt) |
PE (1) | PE20040677A1 (pt) |
PL (1) | PL377025A1 (pt) |
RU (1) | RU2360922C2 (pt) |
TW (1) | TW200409641A (pt) |
UY (1) | UY27893A1 (pt) |
WO (1) | WO2004006839A2 (pt) |
ZA (1) | ZA200501118B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301431D0 (sv) * | 2003-05-19 | 2003-05-19 | Dermagen | Novel antimicrobial peptides |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
BRPI0507177A (pt) * | 2004-01-27 | 2007-06-26 | Bayer Pharmaceuticals Corp | agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso |
DE602005005476T2 (de) * | 2004-05-21 | 2009-03-05 | Eli Lilly And Co., Indianapolis | Selektive peptidische agonisten des vpac2-rezeptors |
ATE412010T1 (de) * | 2004-05-21 | 2008-11-15 | Lilly Co Eli | Selektive peptidische agonisten des vpac2- rezeptors |
CA3090413C (en) | 2004-06-04 | 2023-10-10 | Abbott Diabetes Care Inc. | Glucose monitoring and graphical representations in a data management system |
CN101001639A (zh) * | 2004-06-12 | 2007-07-18 | 拜尔药品公司 | 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法 |
US20080085860A1 (en) * | 2004-08-18 | 2008-04-10 | Eli Lilly And Company | Selective Vpac2 Receptor Peptide Agonists |
WO2006023359A2 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
WO2006042152A2 (en) | 2004-10-08 | 2006-04-20 | Forbes Medi-Tech (Research) Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
US7595294B2 (en) | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
US20090170775A1 (en) * | 2004-10-08 | 2009-07-02 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide compositions |
US20070293429A1 (en) * | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
US20080214440A1 (en) * | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
US20060159737A1 (en) * | 2004-11-19 | 2006-07-20 | Steffen Panzner | Pharmaceutical compositions for local administration |
DE602005014672D1 (de) * | 2004-12-21 | 2009-07-09 | Lubrizol Ltd | Zusammensetzungen |
ES2365410T3 (es) * | 2005-04-08 | 2011-10-04 | Amylin Pharmaceuticals, Inc. | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. |
EP1896048A4 (en) * | 2005-05-06 | 2010-11-03 | Bayer Pharmaceuticals Corp | PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE |
US20080194482A1 (en) * | 2005-08-11 | 2008-08-14 | Jorge Alsina-Fernandez | Selective Apac2 Receptor Peptide Agonists |
EP1942941A1 (en) * | 2005-10-26 | 2008-07-16 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
AU2007220775A1 (en) * | 2006-02-28 | 2007-09-07 | Eli Lilly And Company | Selective VPAC2 receptor peptide agonists |
EP2011506A1 (en) * | 2007-07-05 | 2009-01-07 | Nestec S.A. | Supplementation of maternal diet |
WO2010021752A1 (en) * | 2008-08-21 | 2010-02-25 | Alvine Pharmaceuticals, Inc. | Formulation for oral administration of proteins |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
EP3177309A4 (en) * | 2014-08-06 | 2018-08-15 | Vascular Biosciences | Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same |
WO2016168760A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
WO2017181031A2 (en) | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6972319B1 (en) * | 1999-09-28 | 2005-12-06 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use |
-
2003
- 2003-07-11 RU RU2005103396/13A patent/RU2360922C2/ru not_active IP Right Cessation
- 2003-07-11 PL PL377025A patent/PL377025A1/pl unknown
- 2003-07-11 TW TW092118986A patent/TW200409641A/zh unknown
- 2003-07-11 DO DO2003000669A patent/DOP2003000669A/es unknown
- 2003-07-11 GT GT200300142A patent/GT200300142A/es unknown
- 2003-07-11 CN CNA038166445A patent/CN101405298A/zh active Pending
- 2003-07-11 HN HN2003000217A patent/HN2003000217A/es unknown
- 2003-07-11 UY UY27893A patent/UY27893A1/es not_active Application Discontinuation
- 2003-07-11 AU AU2003267990A patent/AU2003267990A1/en not_active Abandoned
- 2003-07-11 BR BR0312621-8A patent/BR0312621A/pt not_active IP Right Cessation
- 2003-07-11 CA CA002491279A patent/CA2491279A1/en not_active Abandoned
- 2003-07-11 WO PCT/US2003/021761 patent/WO2004006839A2/en active Application Filing
- 2003-07-11 AR AR20030102511A patent/AR040548A1/es unknown
- 2003-07-11 JP JP2004521702A patent/JP2006506969A/ja active Pending
- 2003-07-11 MX MXPA04012305A patent/MXPA04012305A/es unknown
- 2003-07-11 PE PE2003000697A patent/PE20040677A1/es not_active Application Discontinuation
- 2003-07-11 US US10/618,126 patent/US7378494B2/en not_active Expired - Fee Related
- 2003-07-11 EP EP03748938A patent/EP1578358A2/en not_active Withdrawn
-
2004
- 2004-12-01 IL IL165499A patent/IL165499A/en not_active IP Right Cessation
-
2005
- 2005-02-08 ZA ZA200501118A patent/ZA200501118B/en unknown
-
2008
- 2008-05-23 US US12/154,468 patent/US20090258826A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090258826A1 (en) | 2009-10-15 |
DOP2003000669A (es) | 2004-01-31 |
EP1578358A2 (en) | 2005-09-28 |
WO2004006839A2 (en) | 2004-01-22 |
GT200300142A (es) | 2004-03-17 |
RU2360922C2 (ru) | 2009-07-10 |
PE20040677A1 (es) | 2004-10-29 |
ZA200501118B (en) | 2006-08-30 |
US20040058870A1 (en) | 2004-03-25 |
MXPA04012305A (es) | 2005-02-25 |
IL165499A (en) | 2010-12-30 |
US7378494B2 (en) | 2008-05-27 |
RU2005103396A (ru) | 2005-09-20 |
JP2006506969A (ja) | 2006-03-02 |
AU2003267990A1 (en) | 2004-02-02 |
HN2003000217A (es) | 2004-07-26 |
UY27893A1 (es) | 2003-12-31 |
CN101405298A (zh) | 2009-04-08 |
TW200409641A (en) | 2004-06-16 |
PL377025A1 (pl) | 2006-01-23 |
AR040548A1 (es) | 2005-04-13 |
CA2491279A1 (en) | 2004-01-22 |
IL165499A0 (en) | 2006-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312621A (pt) | Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap) | |
AU2017279636B2 (en) | Modified Vasoactive Intestinal Peptides | |
CA2832581C (en) | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) | |
AU2015276203B2 (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
Becker | Insulin glulisine complementing basal insulins: a review of structure and activity | |
US20120184488A1 (en) | Insulin analogues of enhanced receptor-binding specificity | |
Peterson | Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir | |
MY131983A (en) | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use | |
EP2548570A1 (en) | Pharmaceutical composition for treating a metabolic syndrome | |
NZ588857A (en) | Isoform-specific insulin analogue for control blood sugar levels | |
TW201609797A (zh) | 雙重glp-1/升糖素受體促效劑 | |
CN101189021A (zh) | 用于控制、预防和治疗肥胖和进食障碍的组合物和方法 | |
Vazquez-Carrera et al. | Insulin analogues in the management of diabetes | |
JPWO2004037859A1 (ja) | Glp−1誘導体及びその経粘膜吸収型製剤 | |
CZ9904360A3 (cs) | Použití amylinu nebo agonisty amylinu pro výrobu léku k léčení nebo prevenci obezity u člověka | |
BRPI0507177A (pt) | agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso | |
US20120053118A1 (en) | Methods for affecting body composition using amylin agonists | |
KR20170106373A (ko) | 선택적 신호전달 특성 및 감소된 유사분열촉진을 갖는 인슐린 유사체 | |
Patil et al. | Role of insulin in management of type 2 diabetes mellitus | |
JP2002522355A (ja) | 新規な混合アミリン活性化合物 | |
Watson et al. | Biochemical characterization of circulating Met-enkephalins in canine endotoxin shock | |
Mohan | Which insulin to use? Human or animal? | |
Hosotani et al. | Synthetic neuromedin C stimulates exocrine pancreatic secretion in dogs and rats | |
Kesavadev et al. | Newer Insulins on the Horizon | |
Khalil et al. | A Review on the Strategies of Treatment of Type-2 Diabetes Mellitus: Focus on Vildagliptin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |